Furthermore, the synergistic combination therapy using the anti-PD-1 antibody camrelizumab and the VEGFR inhibitor apatinib has been well-received in OSCC, showing good tolerability, no serious adverse effects, and less than 10% of remaining live tumor cells.254. Here, PDCD1 is linked to neoplasm.